InnerCap Tech Inc v. Walmart Inc

I. Executive Summary and Procedural Information

• Parties & Counsel:
  • Plaintiff: INNERCAP Technologies, Inc. (Florida)
  • Defendant: Walmart Inc. (Delaware)
  • Plaintiff's Counsel: Farnan LLP
• Case Identification: 1:26-cv-00488, D. Del., 04/27/2026
• Venue Allegations: Venue is alleged to be proper in the District of Delaware because Walmart is a Delaware corporation and is alleged to have committed acts of infringement in the district, including by selling the accused products through its retail locations and online marketplace.
• Core Dispute: Plaintiff alleges that Defendant's capsule-in-capsule vitamin and supplement products infringe a patent related to multi-compartment capsular delivery systems designed to separate ingredients in different physical states.
• Technical Context: The technology addresses the challenge of combining chemically or physically incompatible ingredients, such as oils and solid powders, into a single oral dosage form for nutritional supplements.
• Key Procedural History: The complaint notes that the patent-in-suit was the subject of a supplemental examination requested on October 15, 2025. On October 31, 2025, the U.S. Patent and Trademark Office (USPTO) determined that none of the eleven prior art references submitted raised a substantial new question of patentability, which may strengthen the patent's presumption of validity against those references.

Case Timeline

Date	Event
2002-04-10	'612 Patent Priority Date
2010-03-02	'612 Patent Issue Date
2025-10-15	Supplemental Examination of '612 Patent Requested
2025-10-31	USPTO Concludes No Substantial New Question of Patentability for '612 Patent
2026-04-27	Complaint Filing Date

II. Technology and Patent(s)-in-Suit Analysis

U.S. Patent No. 7,670,612 - "Multi-phase, multi-compartment capsular delivery apparatus and methods for using same"

• Patent Identification: U.S. Patent No. 7,670,612 ("Multi-phase, multi-compartment capsular delivery apparatus and methods for using same"), issued March 2, 2010.

The Invention Explained

• Problem Addressed: Prior to the invention, it was difficult to combine multiple active ingredients into a single conventional capsule if they existed in different physical states (e.g., solid vs. liquid), were chemically incompatible, or required different release profiles in the body Compl. ¶7 This forced compromises that could lead to ingredient instability, reduced efficacy, or the inability to co-deliver certain combinations Compl. ¶7 '612 Patent, col. 5:5-14
• The Patented Solution: The patent discloses a multi-compartment, capsule-in-capsule system that physically separates different ingredients within a single dosage form '612 Patent, abstract As illustrated in the patent's figures, this can be achieved by placing a smaller, secondary capsule containing one type of ingredient (e.g., a solid) inside a larger, primary capsule containing another (e.g., a liquid), thereby enabling stable co-formulation and optionally allowing for staged release of the contents '612 Patent, Fig. 2 '612 Patent, col. 8:5-17
• Technical Importance: This technology enables the stable and compatible delivery of complex combination supplement and drug products that previously could not be effectively co-formulated in a single dose Compl. ¶7

Key Claims at a Glance

• The complaint asserts infringement of at least independent claim 33 of the '612 Patent Compl. ¶24
• The essential elements of Claim 33 are:
  • A multi-compartment capsule, comprising:
  • a first receiving chamber comprising at least one oil in immediate release form; and
  • a second receiving chamber containing only solid ingredients and comprising at least one active ingredient in a solid state and formulated in a manner allowing for a time-delayed dissolution and release of said solid active ingredient,
  • wherein the ingredients contained in said first receiving chamber are different from the ingredients of said second receiving chamber,
  • and wherein said second receiving chamber is enveloped by said first receiving chamber,
  • and wherein the multi-compartment capsule is a hard shell capsule.
• The complaint notes that Claim 33 is representative of the asserted claims, suggesting other claims may be asserted later Compl. ¶25

III. The Accused Instrumentality

Product Identification

• The complaint identifies the accused products as the "Ritual" and "Daily Nouri" lines of capsule-in-capsule supplements offered for sale and sold by Walmart Compl. ¶2 Compl. ¶15 Specific examples include "Ritual Essentials Prenatal Multivitamins" and "Daily Nouri Digestive Support Probiotic" Compl. ¶¶3-4

Functionality and Market Context

• The accused products are described as having a capsule-in-capsule or "nested capsule" design Compl. ¶15 The complaint alleges these products contain an oil-based ingredient in the outer capsule (the first receiving chamber) and solid, powdered, or lyophilized ingredients in the inner capsule (the second receiving chamber) Compl. ¶2 Compl. ¶14 For example, the Ritual product allegedly contains oil-based omega-3 DHA in the outer capsule and dry, water-soluble vitamins in the inner capsule Compl. ¶42 The Nouri product allegedly contains plant-based omega oil in the outer capsule and probiotic live cultures in the inner capsule Compl. ¶43 Marketing materials cited in the complaint state the inner capsule is designed for delayed release to enhance absorption or survival of probiotics during digestion Compl. ¶37 Compl. ¶39

IV. Analysis of Infringement Allegations

'612 Patent Infringement Allegations

Claim Element (from Independent Claim 33)	Alleged Infringing Functionality	Complaint Citation	Patent Citation
a first receiving chamber comprising at least one oil in immediate release form	The outer capsule of the accused products allegedly contains an oil ingredient (e.g., omega-3 DHA in Ritual products, ahiflower omega oil in Nouri products) for immediate release.	¶¶31-34	col. 96:13-15
a second receiving chamber containing only solid ingredients and comprising at least one active ingredient in a solid state and formulated in a manner allowing for a time-delayed dissolution and release of said solid active ingredient	The inner capsule allegedly contains only solid, powdered, or lyophilized ingredients (e.g., vitamins or probiotics) and is described in marketing as a "delayed-release" capsule designed to dissolve later in the small intestine. Figure 5 shows the product label for the Nouri product, which states its capsules are formulated "to survive harsh stomach acid."	¶¶35-39	col. 96:16-21
wherein the ingredients contained in said first receiving chamber are different from the ingredients of said second receiving chamber	The complaint alleges the products separate oil-soluble ingredients in the outer capsule from water-soluble or dry ingredients in the inner capsule. Figure 6, a supplement facts sheet for the Ritual product, is presented with annotations to show the separation of oil-soluble ingredients (e.g., Vitamin D, Omega-3 DHA, Vitamin K2) from water-soluble ones (e.g., Folate, Iron, B12).	¶¶41-43	col. 96:22-24
and wherein said second receiving chamber is enveloped by said first receiving chamber	The products are alleged to have a "capsule-within-a-capsule" or "nested capsule" structure. Figure 7 provides an annotated image of a Ritual product to illustrate the inner capsule ("second receiving chamber") being enveloped by the outer capsule ("first receiving chamber").	¶¶45-47	col. 96:24-25
and wherein the multi-compartment capsule is a hard shell capsule	The capsules are alleged to be hard shell capsules made of materials such as "hypromellose and gellan gum" (for Ritual) or "vegetable cellulose" (for Nouri).	¶¶49-51	col. 96:29-31

Identified Points of Contention

• Scope Questions: The analysis may raise a question as to what constitutes being "formulated in a manner allowing for a time-delayed dissolution." The complaint relies on marketing claims of delayed release Compl. ¶37 Compl. ¶39 The litigation may focus on whether this marketing language is sufficient to meet the claim limitation, or if specific technical evidence of a formulation designed for delay, beyond that of a standard capsule, is required.
• Technical Questions: A key technical question may be whether the accused "vegan" capsules, allegedly made of materials like hypromellose or vegetable cellulose Compl. ¶50 Compl. ¶51, fall within the scope of the claim term "hard shell capsule." The evidence needed to prove the "time-delayed" functionality of the inner capsule will also be a central technical issue for the court.

V. Key Claim Terms for Construction

The Term: "formulated in a manner allowing for a time-delayed dissolution and release"

Context and Importance

• This term is critical to infringement, as it defines the required functionality of the inner capsule. The dispute will likely center on the level of technical proof needed to show the accused inner capsule is specifically "formulated" for delay, rather than just inherently taking time to dissolve. Practitioners may focus on this term because the complaint's evidence is primarily based on marketing statements about performance (e.g., "dissolve later in the small intestine") rather than explicit formulation details Compl. ¶37

Intrinsic Evidence for Interpretation

• Evidence for a Broader Interpretation: Claim 33 itself does not specify a particular mechanism (e.g., a coating) to achieve the delay, only that the formulation allows for it '612 Patent, col. 96:16-21 This may support an interpretation that any formulation resulting in a delayed release meets the limitation.
• Evidence for a Narrower Interpretation: The patent specification repeatedly discusses "time-release coatings" as a method for controlling release '612 Patent, col. 44:31-34 A party could argue that the context of the patent suggests "formulated" requires a specific engineering step, such as applying a coating, rather than just selecting a standard capsule material.

The Term: "hard shell capsule"

Context and Importance

• This term's construction is vital because the accused products are alleged to use modern "vegan" capsule materials like hypromellose and vegetable cellulose Compl. ¶¶50-51 The case may turn on whether "hard shell capsule" is limited to traditional gelatin capsules or encompasses these other materials.

Intrinsic Evidence for Interpretation

• Evidence for a Broader Interpretation: The patent specification explicitly lists hydroxypropyl methyl-cellulose (HPMC), a primary component of many vegan capsules, as a potential material for the capsule walls '612 Patent, col. 2:30-34 This provides direct support for a construction that includes the materials allegedly used in the accused products.
• Evidence for a Narrower Interpretation: The "Background of the Invention" section contrasts "hard gelatin capsules" with "soft elastic capsules," potentially suggesting that "hard shell" was understood by the inventor in the traditional sense of a two-piece gelatin capsule '612 Patent, col. 2:35-51

VI. Other Allegations

• Indirect Infringement: The complaint does not provide sufficient detail for analysis of indirect infringement.
• Willful Infringement: The complaint does not contain specific allegations of willful infringement or pre-suit knowledge of the '612 Patent.

VII. Analyst's Conclusion: Key Questions for the Case

This case will likely hinge on questions of claim construction and the evidentiary burden for proving infringement. The central issues for the court to resolve include:

• A core issue will be one of definitional scope: Does the claim term "hard shell capsule," as used in the patent, read on the "vegan" capsules allegedly made of hypromellose and vegetable cellulose, or is its meaning limited to traditional gelatin capsules?
• A key evidentiary question will be one of functional proof: What level of evidence is required to demonstrate that the inner capsule is "formulated in a manner allowing for a time-delayed dissolution"? Will the marketing claims of enhanced digestive survival cited in the complaint be sufficient, or will technical data on the capsule's dissolution properties be necessary to prove infringement?
• A third question concerns characterization of the prior art: In light of the USPTO's supplemental examination finding of no substantial new question of patentability, the court will need to assess the strength and relevance of any invalidity arguments and prior art presented by the defendant that may overlap with what the USPTO has already reviewed.